# Use of Autologous Adipose-Derived Stem/Stromal Cells (AD-cSVF) in Symptomatic Benign Prostate Hypertrophy

> **NCT02961114** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Robert W. Alexander, MD, FICS**

## Conditions studied

- BPH
- Nocturia
- BPH With Urinary Obstruction
- Prostatism
- Prostate Inflammation

## Interventions

- **PROCEDURE:** Microcannula Harvest Adipose
- **DEVICE:** Centricyte 1000
- **BIOLOGICAL:** IV Sterile Normal Saline

## Key facts

- **NCT ID:** NCT02961114
- **Lead sponsor:** Robert W. Alexander, MD, FICS
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-11-01
- **Primary completion:** 2022-12
- **Final completion:** 2023-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** COVID restrictions prevent patient enrollment or treatment. Clinical Trial facility is being closed due to viral limitations and loss of staff to perform
- **Last updated:** 2021-01-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02961114

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02961114, "Use of Autologous Adipose-Derived Stem/Stromal Cells (AD-cSVF) in Symptomatic Benign Prostate Hypertrophy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02961114. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*